Poland· PL-100019657

DISTREPTAZA

A streptokinase product containing streptodornasum + streptokinasum, registered in Poland by Synthaverse S.A.. The same ATC class is registered in 3 of our 19 countries.

ATC B01AD01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDISTREPTAZAATCB01AD01REGISTER NO.PL-100019657PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Streptokinase is registered in 3 of 19 countries.

Countries holding a registration under ATC B01AD01 (streptokinase), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose

Streptokinase · ATC B01AD01

3 / 19 countries

  • Finlandprice
  • Norwayprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Streptodornasum + Streptokinasum
Manufacturer
Synthaverse S.A.
Country
Poland (PL)
ATC code
B01AD01
ATC class
Streptokinase
Defined daily dose
1.5 MIO, E
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990021116
  • gtin
    05909990695249

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

130 interactions on record for streptokinase.

Graded by severity as the source publishes them — 46 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Streptokinase · interactions on record

130 records

  • 46 severe
  • 84 moderate

Most severe, free to view

  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Streptokinase in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All streptokinase products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Bulgaria · Дистрептаза
  • Spain · Ernodasa, Varidasa
  • Hungary · Distraza
  • Malta · Distreptaza

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c981fd3f-2b57-49db-9648-bd02795115f9
GET /v1/drugs/c981fd3f-2b57-49db-9648-bd02795115f9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Czopki doodbytnicze",
  "source": "urpl",
  "strength": "1250 j.m. + 15000 j.m.",
  "packaging": "05909990021116 ¦ Rp ¦ 3263\n6 szt.\n05909990695249 ¦ Rp ¦ 49658\n10 szt.",
  "substance": "Streptodornasum 1250 j,m. + Streptokinasum 15000 j.m.",
  "common_name": "Streptodornasum + Streptokinasum",
  "pl_product_id": "100019657",
  "pozwolenie_nr": "00211",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about streptokinase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.